ImmunoGen presents initial data from Phase 1b FORWARD II triplet cohort
ImmunoGen announced initial safety and overall response data from the Phase 1b FORWARD II triplet cohort evaluating mirvetuximab in combination with carboplatin and Avastin in patients with recurrent, platinum-sensitive ovarian cancer at the European Society for Medical Oncology 2019 Congress in Barcelona, Spain. In 41 patients with recurrent platinum-sensitive disease with medium or high folate receptor alpha expression levels who have received up to two prior lines of therapy, the confirmed overall response rate for the triplet was 83%, with a complete response rate of 17%. In a subset of 31 patients with only 1 prior line, the confirmed ORR was 90%, with a CR rate of 19%. These efficacy outcomes are encouraging relative to those reported in similar patient populations for other carboplatin and bevacizumab-based triplets. With a median follow up of 9.3 months, progression-free survival data are maturing. The combination of full dose mirvetuximab, carboplatin and bevacizumab is well tolerated. No new safety signals were seen; adverse events observed with the triplet were as expected based on the side effect profiles of each agent, with thrombocytopenia as the most common cause of drug-related discontinuations. Post-carboplatin, mirvetuximab and bevacizumab continuation/maintenance is well tolerated.